Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 15, 2018. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Transaction Price | Total Volume Acquired |
|---|---|---|---|
| January 11, 2018 | Ordinary Shares (25 pence each) | £13.3440 | 8,242.032 shares |
Note: The total volume is the aggregate of individual transactions listed below.
Material Changes and Transaction Details
The filing details the acquisition of ordinary shares by nine individuals (eight PDMRs and one person closely associated) on January 11, 2018. All transactions were executed on the London Stock Exchange (XLON) at a uniform price of £13.3440 per share. The nature of all transactions was the acquisition of shares following the re-investment of dividends paid to shareholders on that date.
- Ms E Walmsley (CEO): Acquired 473.274 shares.
- Mr R G Connor (President, Global Manufacturing & Supply): Acquired 82.400 shares.
- Mr L Debruyne (President, Global Vaccines): Acquired 851.563 shares.
- Mr S Dingemans (CFO): Acquired 919.518 shares.
- Mr D S Redfern (Chief Strategy Officer): Acquired 1,552.174 shares.
- Ms C Thomas (SVP, HR): Acquired 599.748 shares.
- Mr P C Thomson (President, Global Affairs): Acquired 728.198 shares.
- Dr P J T Vallance (President, R&D): Acquired 2,918.217 shares.
- Mrs K Thomson (PCA of Mr P C Thomson): Acquired 137.540 shares.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory disclosure of insider share transactions.
Key Facts for Investor Verification
- Verify that the share acquisitions were indeed part of a Dividend Re-investment Plan (DRIP) and not discretionary open-market purchases.
- Confirm the dividend payment date of January 11, 2018, aligns with the company's declared dividend schedule.
- Check the London Stock Exchange trading data for January 11, 2018, to validate the transaction price of £13.3440.
- Review the company's annual report (Form 20-F) for broader financial performance metrics not included in this filing.